Literature DB >> 19558188

Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.

Henriette E Meyer zu Schwabedissen1, Richard B Kim.   

Abstract

Drug uptake transporters are now increasingly recognized as clinically relevant determinants of variable drug responsiveness and unexpected drug-drug interactions. Emerging evidence strongly suggests members of the organic anion transporting polypeptide (OATP) family appear to be particularly important to the disposition of many drugs in clinical use today. Specifically, the liver-enriched OATP1B subfamily members OATP1B1 and OATP1B3 exhibit broad substrate specificity and the ability to transport drugs which are ligands for xenobiotic sensing nuclear receptors such as the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR). Accordingly, OATP1B transporters may indirectly regulate expression of drug metabolism genes via modulation of the intracellular concentration of PXR and CAR ligands. Moreover, a number of functionally important single nucleotide polymorphisms (SNPs) in OATP1B transporters have been described. In this review, a brief summary of known SNPs in PXR and CAR will be followed by an in-depth outline of OATP1B1 and OATP1B3 transporters particularly in relation to the known SNPs in these OATPs and the interplay between OATP1B transporters with PXR and CAR, both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558188     DOI: 10.1021/mp9000298

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  23 in total

1.  The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.

Authors:  Lan Fan; Gan Zhou; Dong Guo; Ya-Li Liu; Wang-Qing Chen; Zhao-Qian Liu; Zhi-Rong Tan; Deng Sheng; Hong-Hao Zhou; Wei Zhang
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

2.  Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions.

Authors:  Chandra Prakash; Baltazar Zuniga; Chung Seog Song; Shoulei Jiang; Jodie Cropper; Sulgi Park; Bandana Chatterjee
Journal:  Nucl Receptor Res       Date:  2015

3.  Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma.

Authors:  Tasmin Reuter; Rolf Warta; Dirk Theile; Andreas D Meid; Juan Pablo Rigalli; Carolin Mogler; Esther Herpel; Niels Grabe; Bernd Lahrmann; Peter K Plinkert; Christel Herold-Mende; Gerhard Dyckhoff; Walter Emil Haefeli; Johanna Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-07-04       Impact factor: 3.000

4.  Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.

Authors:  Alain Li-Wan-Po; Peter Farndon; Charles Craddock; Michael Griffiths
Journal:  Eur J Clin Pharmacol       Date:  2010-01-29       Impact factor: 2.953

Review 5.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

Review 6.  Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver.

Authors:  Jeff L Staudinger; Sarah Woody; Mengxi Sun; Wenqi Cui
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

Review 7.  Organic anion-transporting polypeptides.

Authors:  Bruno Stieger; Bruno Hagenbuch
Journal:  Curr Top Membr       Date:  2014       Impact factor: 3.049

8.  Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver.

Authors:  Margaret M S Thomson; Ronald N Hines; Erin G Schuetz; Bernd Meibohm
Journal:  Drug Metab Dispos       Date:  2016-04-20       Impact factor: 3.922

Review 9.  Bile formation and secretion.

Authors:  James L Boyer
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

10.  Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.

Authors:  Xinyan Zhang; Camlin Tierney; Mary Albrecht; Lisa M Demeter; Gene Morse; Robin DiFrancesco; Carrie Dykes; Hongyu Jiang; David W Haas
Journal:  Ther Drug Monit       Date:  2013-04       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.